Protein kinase c inhibitor sotrastaurin in de novo liver transplant recipients: A randomized phase ii trial

American Journal of Transplantation

Volumn 15, Issue 5, 2015, Pages 1283-1292

  Pascher, A ^a   De Simone, P ^b   Pratschke, J ^c   Salame E ^d   Pirenne, J ^e   Isoneimi, H ^f   Bijarnia, M ^g   Krishnan, I ^h   Klupp, J ^h  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL OF PISA   (Italy)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d SERVICE DE DERMATOLOGIE   (France)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^g NOVARTIS HEALTHCARE PVT LTD   (India)

^h NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Clinical research; hepatology; immunemodulation; immunosuppression; liver transplantation; practice

Indexed keywords

CORTICOSTEROID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; SOTRASTAURIN; TACROLIMUS; ENZYME INHIBITOR; IMMUNOSUPPRESSIVE AGENT; PROTEIN KINASE C; PYRROLE DERIVATIVE; QUINAZOLINE DERIVATIVE;

ABDOMINAL PAIN; ACUTE GRAFT REJECTION; ADULT; ANEMIA; ARTICLE; BACKACHE; CHOLANGITIS; CHOLESTASIS; CONSTIPATION; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; GRAFT RECIPIENT; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERTENSION; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INSOMNIA; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY FUNCTION; LEUKOPENIA; LIVER FUNCTION; LIVER GRAFT; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PAIN; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; TACHYCARDIA; THROMBOCYTOPENIA; TREATMENT DURATION; TREMOR; URINARY TRACT INFECTION; VOMITING; WOUND COMPLICATION; AGED; ANTAGONISTS AND INHIBITORS; BIOPSY; CLINICAL TRIAL; GRAFT REJECTION; INCIDENCE; KAPLAN MEIER METHOD; KIDNEY TRANSPLANTATION; LIVER FAILURE; LIVER TRANSPLANTATION; MIDDLE AGED; MORTALITY; PROCEDURES; TIME; TREATMENT OUTCOME;

ADULT; AGED; BIOPSY; ENZYME INHIBITORS; FEMALE; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KAPLAN-MEIER ESTIMATE; KIDNEY TRANSPLANTATION; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PROTEIN KINASE C; PYRROLES; QUINAZOLINES; TACROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84928087693     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13175     Document Type: Article

References (8)

1. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349: 931-940.
2. Lebron Gallardo, Herrera M, Gutierrez ME, et al. Risk factors for renal dysfunction in the postoperative course of liver transplant. Liver Transpl 2004; 11: 1379-1385.
3. Pawarode A, Fine DM, Thuluwath PJ,. Independent risk factors and natural history of renal dysfunction in liver transplant recipients. Liver Transpl 2003; 9: 741-747.
4. Sharma P, Welch K, Eikstadt R, Marrero JA, Fontana RJ, Lok AS,. Renal outcomes after liver transplantation in the model for end-stage liver disease era. Liver Transpl 2009; 15: 1142-1148.
5. Evenou JP, Wagner J, Zenke G, Brinkmann V, Wagner K, Kovarik J, et al. The potent protein kinase C-selective inhibitor AEB071 (sotrastaurin) represents a new class of immunosuppressive agents affecting early T-cell activation. J Pharmacol Exp Ther 2009; 330: 792-801.
6. Russ GR, Tedesco-Silva H, Kuypers DR, et al. Efficacy of sotrastaurin plus tacrolimus after de novo kidney transplantation: Randomized, phase II trial results. Am J Transplant 2013; 13: 1746-1756.
7. Tedesco-Silva H, Kho MM, Hartmann A, et al. Sotrastaurin in calcineurin inhibitor-free regimen using everolimus in de novo kidney transplant recipients. Am J Transplant 2013; 13: 1757-1768.
8. Kovarik JM, Neuhaus P, Cillo U, et al. Sotrastaurin single-dose pharmacokinetics in de novo liver transplant recipients. Transpl Int 2011; 24: 276-228.